Recon: Emergent to resume J&J vaccine production; Sanofi raises profit forecast

• Citing New Data, Pfizer Outlines Case for Booster Shots (NYTimes)
• J&J says US FDA agrees to extend shelf life of its COVID-19 vaccine (Reuters)
• Emergent to resume J&J COVID-19 vaccine production at Baltimore plant (Reuters) (WSJ)
• U.S. House panel seeks J&J documents on baby powder bankruptcy plans (Reuters)
• AstraZeneca CEO hopeful COVID-19 vaccine may still have role in U.S. (Reuters)
• U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir (Reuters)
• Deep Genomics raises $180 million to automate drug discovery (STAT)
• Doctors Blast Biogen Alzheimer Approval as ‘Regulatory Failure’ (Bloomberg) (Endpoints) (NEJM 1, 2, 3)
• Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices (STAT)

• Sanofi raises profit forecast after second quarter beat (Reuters) (FT)
• New Zealand gives provisional nod to AstraZeneca's COVID-19 vaccine (Reuters)
• AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges (Reuters)
• AstraZeneca exploring options for COVID-19 vaccine business – executive (Reuters)
• Israel to offer Pfizer booster jab to the over 60s – reports (Reuters)
• AstraZeneca vaccine shipped to Canada, Mexico before adequate plant inspections (Reuters)
• Pharma firm Advanz fined after thyroid drug price hike of 6,000% (The Guardian)

• Cuba says Iran to start producing one of its COVID-19 vaccines (Reuters)
• McConnell aims to boost U.S. Republican vaccination rate by countering 'bad advice' (Reuters)

• FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost? (STAT)
• Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D (STAT)
• Merck and Pfizer back a Michigan startup's mission to advance tumor profiling (Endpoints)
• AstraZeneca and Amgen quietly admit tezepelumab defeat as the Dupixent challenger heads to FDA (Endpoints)
• Resilience shells out $110M for bluebird bio site, kickstarting new collaboration (Endpoints)
• Flush with cash, Rakuten billionaire Mickey Mikitani looks to take his photoimmunotherapy platform global (Endpoints)
• Eli Lilly teams up with KRAS drug pioneer Yi Liu targeting small molecule I/O with $70M upfront (Endpoints)
• Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing (Pink Sheet)
• As leading synbio players bask in spotlight, US/China startup lands $100M to find its own niche (Endpoints)
• Waiting For Inspections, Biocon Seeks US FDA Stance On Mutual Recognition Agreement Route (Pink Sheet)
• Novartis China Drive Paying Off, Sales Soar On Reimbursement Inclusion (Scrip)

• Thermo Fisher slashes COVID-19 testing guidance by $900M (MedtechDive)
• Medtronic nets heartening FDA nod for AI algorithms to detect afib, arrhythmia (Fierce)
• As Stryker boosted by electives comeback, CEO downplays delta variant risk to procedures (MedtechDive)
• Exo nabs $220M as hand-held ultrasound race heats up (Fierce)
• Baxter Reports Second-Quarter 2021 Results (Press)
• Strata Oncology gets $90M boost from Pfizer, Merck and more for genomic cancer testing (Fierce)

• Opioid Distributors Pin Blame On Others As W.Va. Trial Ends (Law360)
• Endo, Arnold & Porter Accused Of Cover-Up In Opioid MDL (Law360)
• McKinsey Says Cherokee Opioid Suit Can't Go To State Court (Law360)
• Pfizer Court Fight Could Legalize Medicare Copays and Unleash ‘Gold Rush’ in Sales (KHN)